Development and evaluation of an ultrasensitive free VEGF-A immunoassay for analysis of human aqueous humor.

Novel bifunctional VEGF-A neutralizing therapies are being developed for the treatment of retinal vascular diseases such as age-related macular degeneration and diabetic retinopathy. In developing new therapeutic drugs, only small aqueous humor sample volumes are available for analyzing several parameters. Highly sensitive detection methods must be applied in analyzing VEGF-A levels in ocular fluids in order to demonstrate VEGF-A suppression following drug administration.

Immunogenicity testing of therapeutic antibodies in ocular fluids after intravitreal injection.

Aim: High drug concentrations in ocular fluids after intravitreal administration preclude the use of drug-sensitive immunoassays. A drug-tolerant immunoassay is therefore desirable for immunogenicity testing in ophthalmology.

Experimental: Immune complex (IC) antidrug antibody (ADA) assays were established for two species.